Stephanie L. Graff, MD
A greater understanding of the genomics of patients with hormone receptor (HR)–positive breast cancer is enabling physicians to offer more personalized de-escalated and escalated treatment strategies for those with lower-risk disease or at a high risk of recurrence, explained Stephanie L. Graff, MD.
Based on the findings from the MINDACT trial, MammaPrint, which is an assay created to collectively assess 70 genes, was successfully shown to select women at a low risk of recurrence who may not benefit from adjuvant chemotherapy—specifically, those with low-volume, low-grade, and well-differentiated disease.1
These findings were echoed in the phase III TAILORx trial, in which women with early-stage, HR-positive/HER2-negative breast cancer and an intermediate Oncotype DX Breast Recurrence Score were able to forgo chemoendocrine therapy and opt for endocrine therapy alone without compromising outcomes.2
... to read the full story